Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 1;31(2):191-198.
doi: 10.1097/MNH.0000000000000769.

COVID-19 in patients with glomerular disease

Tabitha Turner-Stokes  1   2 , Helena Edwards  1   2 , Liz Lightstone  1   2
Affiliations
Review

COVID-19 in patients with glomerular disease

Tabitha Turner-Stokes et al. Curr Opin Nephrol Hypertens. .

Abstract

Purpose of review: Managing patients with glomerular disease during the COVID-19 pandemic has been challenging, as the infection risk associated with immunosuppression must be balanced against the need to control severe glomerular disease that can lead to kidney failure. This review provides an overview of COVID-19 and the effectiveness of SARS-CoV-2 vaccination in patients with glomerular disease.

Recent findings: Registry data, although biased towards outcomes of hospitalized patients, suggest that the mortality from COVID-19 is higher in patients with glomerular disease than in the general population. Glucocorticoid use prior to SARS-CoV-2 infection is associated with adverse outcomes from COVID-19. Rituximab significantly attenuates serological responses to both natural infection and vaccination against SARS-CoV-2, although it is not clear whether this leads to adverse outcomes. Case reports of disease flares occurring after vaccination have been reported, but causality in any of these cases has yet to be proven and the absolute risk remains very small.

Summary: Patients with glomerular disease represent an at-risk group for severe COVID-19 disease and vaccination is key to reducing this risk. As immunosuppressed patients demonstrate an attenuated response to vaccination, the efficacy of a third primary dose followed by a subsequent booster is being investigated.

PubMed Disclaimer

References

    1. Kronbichler A, Gauckler P, Windpessl M, et al. COVID-19: implications for immunosuppression in kidney disease and transplantation. Nat Rev Nephrol 2020; 16:365–367.
    1. NICE guideline. COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders. 2020. https://www.nice.org.uk/guidance/ng167 .
    1. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet Lond Engl 2020; 395:1033–1034.
    1. Vaninov N. In the eye of the COVID-19 cytokine storm. Nat Rev Immunol 2020; 20:277.
    1. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130:2620–2629.

Publication types

Substances